visceral adiposity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Coninae Fleming, 1822 — synonyms: Conulinae Rafinesque, 1815 (inv.); Textiliinae da Motta, 1995 (n.a.) Clathurellinae H. Adams & A. Adams, 1858 — synonyms: Defranciinae Gray, 1853 (inv.); Borsoniinae A. Bellardi, 1875; Pseudotominae A. Bellardi, 1888; Diptychomitrinae L. Bellardi, 1888; Mitrolumnidae Sacco, 1904; Mitromorphinae Casey, 1904; Lorinae Thiele, 1925 Conorbiinae de Gregorio, 1880—synonym: Cryptoconinae Cossmann, 1896 Mangeliinae P. Fischer, 1883—synonym: Cytharinae Thiele, 1929 Oenopotinae Bogdanov, 1987—synonym: Lorinae Thiele, 1925 sensu Thiele Raphitominae A. Bellardi, 1875—synonyms: Daphnellinae Casey, 1904; Taraninae Casey, 1904; Thatcheriidae Powell, 1942; Pleurotomellinae F. Nordsieck, 1968; Andoniinae Vera-Pelaez, 2002 † Siphopsinae Le Renard, 1995
==== Umeko ==== Koume Kodou (胡堂 小梅, Kodō Koume), also known as "Umeko" (ウメコ), is a ditzy, yet kind-hearted and perky, member of the team who serves as Deka Pink (デカピンク, Deka Pinku), though she frequently claims to be the field leader. Throughout the series, she spends every moment she can in a bubble bath with her three rubber ducks, Umeyo, Umenosuke, and Umegoro. After learning of Sen-chan's feelings for her, she moves in with him, as of the crossover film Mahō Sentai Magiranger vs. Dekaranger. As Deka Pink, Umeko wields the D-Knuckle and D-Stick, which can combine to form the D-Shot and allow her to perform the Twin Cam Shot alongside Jasmine. Using the SP License's Masquerade Mode (マスカレイドモード, Masukareido Mōdo), she can instantaneously change her outfit for disguise purposes. Umeko is portrayed by Mika Kikuchi (菊地 美香, Kikuchi Mika).
In 2024, GoodRx achieved 6% revenue growth with $792.3 million for the full year and turned a net loss into a positive net income of $16.4 million. The company also demonstrated strong operational efficiency, with a 32.8% increase in full-year Adjusted EBITDA. In Q2 2025, GoodRx reported revenue of $203.1 million, a 1.2% increase from the previous year, and a net income of $12.8 million, a significant 92% jump, which resulted in a 6.3% net income margin. However, prescription transaction revenue declined by 3% due to a decrease in monthly active consumers, but this was offset by strong 32% growth in its Pharma Manufacturer Solutions business. GoodRx also saw a 7% decrease in subscription revenue.
Sources: en.wikipedia.org
High doses of some antioxidants may have harmful long-term effects. The Beta-Carotene and Retinol Efficacy Trial (CARET) study of lung cancer patients found that smokers given supplements containing beta-carotene and vitamin A had increased rates of lung cancer. These harmful effects may also be seen in non-smokers, as one meta-analysis including data from approximately 230,000 patients showed that β-carotene, vitamin A or vitamin E supplementation is associated with increased mortality, but saw no significant effect from vitamin C. No health risk was seen when all the randomized controlled studies were examined together, but an increase in mortality was detected when only high-quality and low-bias risk trials were examined separately. As the majority of these low-bias trials dealt with either elderly people, smokers, or people with disease, these results may not apply to the general population. This meta-analysis was later repeated and extended by the same authors, confirming the previous results. These two publications are consistent with some previous meta-analyses that also suggested that vitamin E supplementation increased mortality, and that antioxidant supplements increased the risk of colon cancer. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT study), vitamin E – alone or combined with selenium – had no effect on the risk of prostate cancer. Beta-carotene may also increase lung cancer.
==== MeSH E05.196.922 – titrimetry ==== MeSH E05.196.922.250 – colorimetry MeSH E05.196.922.375 – complement hemolytic activity assay MeSH E05.196.922.500 – conductometry MeSH E05.196.922.625 – neutralization tests MeSH E05.196.922.750 – potentiometry MeSH E05.196.922.875 – skin test end-point titration
The university's mascots are a pair of anthropomorphized wildcats named Wilbur and Wilma. The human figures behind Wilbur and Wilma are kept secret through the year as the mascots appear only in costume. In 1986, Wilbur married his longtime wildcat girlfriend, Wilma. Together, Wilbur and Wilma appear along with the cheerleading squad at most Wildcat sporting events. Arizona's first mascot was a real desert bobcat named "Rufus Arizona", introduced in 1915.
Sources: en.wikipedia.org
===== Other names in the Western world ===== In the last decades, two new important terminologies emerged. Both are commonly used in the Western world in neoshamanic, recreative or pharmaceutical contexts to address ayahuasca-like substances created without the traditional botanical species, due to it being expensive and/or hard to find in these countries. These concepts are surrounded by some controversies involving ethnobotany, patents, commodification and biopiracy:
==== Myasthenia gravis ==== Myasthenia gravis is an autoimmune disease most often caused by antibodies that block acetylcholine receptors, which are responsible for signaling between nerves and muscles. It is often associated with thymic hyperplasia or thymoma, with antibodies produced probably because of abnormally developed T cells. Myasthenia gravis most often develops between young and middle age, causing easy fatiguing of muscle movements. Investigations include demonstrating antibodies (such as against acetylcholine receptors or muscle-specific kinase), and CT scan to detect thymoma or thymectomy. Concerning the thymus, removal of the thymus, called thymectomy, may be considered as a treatment, particularly if a thymoma is found. Other treatments include increasing the duration of acetylcholine action at nerve synapses by decreasing the rate of breakdown. This is done by acetylcholinesterase inhibitors such as pyridostigmine.
Bayer lost some of its trademark rights to heroin (as well as aspirin) under the 1919 Treaty of Versailles following the German defeat in World War I. Use of heroin by jazz musicians in particular was prevalent in the mid-twentieth century, including Billie Holiday, saxophonists Charlie Parker, John Coltrane and Art Pepper, trumpeter and vocalist Chet Baker, guitarist Joe Pass and piano player/singer Ray Charles; a "staggering number of jazz musicians were addicts". It was also a problem with many rock musicians, particularly from the late 1960s through the 1990s. Pete Doherty is also a self-confessed user of heroin. Nirvana lead singer Kurt Cobain's heroin addiction was well documented. Pantera frontman Phil Anselmo turned to heroin while touring during the 1990s to cope with his back pain. Lou Reed's heroin addiction is well known and evident by the many references to the drug in his songs. James Taylor, Taylor Hawkins, Jimmy Page, John Lennon, Eric Clapton, Johnny Winter, Keith Richards, Shaun Ryder, Shane MacGowan and Janis Joplin also used heroin. Many musicians have made songs referencing their heroin usage.
== External links == "Atomic weights and isotopic compositions". physics.nist.gov. Physical Reference Data. National Institute for Standards and Technology. 23 August 2009. "Atomic mass unit". sizes.com. Archived from the original on 2008-01-15.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.